key: cord-0957555-kn87chuh authors: Caméléna, François; Moy, Anne-Clotilde; Dudoignon, Emmanuel; Poncin, Thibaut; Deniau, Benjamin; Guillemet, Lucie; Le Goff, Jérôme; Budoo, Mélissa; Benyamina, Mourad; Chaussard, Maïté; Coutrot, Maxime; Lafaurie, Matthieu; Plaud, Benoît; Mebazaa, Alexandre; Depret, François; Berçot, Béatrice title: Performance of a multiplex polymerase chain reaction panel for identifying bacterial pathogens causing pneumonia in critically ill patients with COVID-19 date: 2020-08-21 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2020.115183 sha: d0736500e5f0ec462ffa5548bee872b040bb7b1d doc_id: 957555 cord_uid: kn87chuh The FilmArray® Pneumonia Plus (FA-PP) panel can provide rapid identifications and semi-quantitative results for many pathogens. We performed a prospective single-center study in 43 critically ill patients with COVID-19, in which we performed 96 FA-PP tests and cultures of blind bronchoalveolar lavage (BBAL). FA-PP detected one or more pathogens in 32% (31/96 of samples), whereas culture methods detected at least one pathogen in 35% (34/96 of samples). The most prevalent bacteria detected were Pseudomonas aeruginosa (n = 14) and Staphylococcus aureus (n = 11) on both FA-PP and culture. The FA-PP results from BBAL in critically ill patients with COVID-19 were consistent with bacterial culture findings for bacteria present in the FA-PP panel; showing sensitivity, specificity, positive and negative predictive value of 95%, 99%, 82% and 100%, respectively. Median turnaround time for FA-PP was 5.5 hours, which was significantly shorter than for standard culture (26 hours) and AST results (57 hours). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease 2019 , has rapidly spread worldwide. Several studies have reported complications of COVID-19, such as bacterial pneumonia, acute respiratory distress syndrome (ARDS) and multiple organ failure syndromes [1] [2] [3] . Recent guidelines for the management of adults critically ill with COVID-19 have suggested the empiric use of antimicrobial agents in patients with respiratory failure [4] . The accurate and timely diagnosis of bacterial pneumonia, particularly in cases of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), is particularly challenging, and this condition remains a major cause of morbidity and mortality [5, 6] . Molecular tests provide a rapid turnaround time (TAT), together with identifications and semi-quantitative results for many pathogens responsive to antimicrobial therapy. Multiplex testing may provide additional information concerning the presence of antibiotic resistance genes, thereby improving antibiotic management [7, 8] . We performed a prospective single-center study on critically ill patients with COVID-19, in which we conducted parallel tests of blind bronchoalveolar lavage (BBAL) by conventional culture and FilmArray® Pneumonia Plus (FA-PP) panel (BioFire, Salt Lake City, US). The aim of this study was to evaluate the performance of FA-PP and to compare its TAT with that of conventional cultures. We conducted a prospective single-center study of consecutive patients admitted to the ICU at the Saint-were excluded from the analysis: aged under 18 years, pregnant or dying within 48 hours of admission. For each patient, BBAL was performed immediately after intubation (or on admission to the ICU if the patient was already intubated) and in cases in which VAP was suspected. We recorded clinical, laboratory and antimicrobial therapy data. The study was approved by the local ethics committee (the ethics committee of Société Française d'Anesthésie Réanimation IRB 00010254-2019-203). BBAL was performed with a sterile catheter and a specimen trap kit. The suction tube was introduced blindly through the endotracheal tube and wedged into the tracheobronchial tree before suction; 50 mL of saline were successively injected and aspirated twice, and the contents of the second aspiration were analyzed, the contents of the first being discarded [9] . Samples were transported immediately to the laboratory. Samples received from 6 pm to 8 am were conserved at +4°C and tested the following morning. We tested the BBAL samples in parallel by FA-PP and conventional culture, and the results were released as soon as they become available. The decision to use FA-PP results for the management of antimicrobial therapy was left to the discretion of the treating physician. We plated 10 µL of BBAL on agar media (BioMérieux, Marcy l'Etoile, France) including blood, colistinnalidixic acid blood and chocolate agars, and incubated the plates in ambient air or under an atmosphere enriched with 5% CO 2 at 35°C. No Gram staining was performed on the BBAL, to protect laboratory staff, as this procedure requires centrifugation, which may generate aerosols. Bacteria were semiquantified by calculating colony-forming units (CFU) per ml (CFU/ml). Culture results were interpreted according to the recommendations of the European Society for Clinical Microbiology and Infectious Diseases [10] , after observation at 18-24 hours, and negative plates were incubated for a further two days, to ensure an absence of bacterial growth, before being classified definitively as negative. A cut-off of 10 4 CFU/ml for significant growth of potential pathogens for BBAL was used. Bacteria were identified by J o u r n a l P r e -p r o o f using MALDI-TOF MS (VITEK-MS, BioMérieux, Marcy-l'Étoile, France), according to the manufacturer's instructions. Antimicrobial susceptibility testing (AST) was performed by the disk diffusion method or with the VITEK 2 (BioMérieux, Marcy-l'Étoile, France), in accordance with the recommendations of the European Committee on Antimicrobial Susceptibility Testing. As recommended by the manufacturer, a dry swab was dipped into the BBAL and then immersed in Sensitivity (Se), specificity (Sp), positive and negative predictive values (PPV and NPV), likelihood ratio and κ index were calculated by comparing the results for conventional culture with those of FA-PP only for bacterial pathogens present in the FA-PP panel. Performance was measured only for bacterial analysis, with bacterial culture used as the gold standard reference method. Two-tailed Mann-Whitney tests were used to compare TAT between the two methods. In total, 96 samples from 43 patients were tested in parallel by FA-PP and conventional BBAL culture. The median age of the patients was 64 years, 86% were male, 27% were obese and 72% had hypertension (Table 1) . On admission to the ICU, 37 (86%) patients were already on invasive mechanical ventilation. In six of these eight samples, the pathogens present were not included in the FA-PP panel (Citrobacter koseri in 4 cases, Stenotrophomonas maltophilia in one case and Enterococcus faecium in one case). S. aureus and Klebsiella aerogenes were recovered from single culture from two samples that tested also negative by FA-PP. Bacterial load was 10 3 colony-forming units (CFU)/mL of culture for both these pathogens, corresponding to a low organism burden. We found that 28 of the bacteria of the FA-PP panel grew to significant levels (i.e. ≥ 10 4 CFU/mL) in culture, with 100% (28/28) presenting ≥ 10 4 copies of bacterial nucleic acid/mL on FA-PP. Another 10 bacteria grew to non-significant levels (i.e. < 10 4 CFU/mL), and 80% (8/10) of these bacteria were found to be present at a level ≥ 10 4 copies/mL by FA- We studied 43 critically ill patients with COVID-19 who underwent BBAL at least once for suspected bacterial pneumonia. A few cases of bacterial pneumonia have been reported in critically ill patients with COVID-19. The diagnosis of bacterial pneumonia in such patients remains challenging, as obtaining distal respiratory samples by bronchoscopy exposes intensivists to a high risk of contamination [1, 2, 11] . We, therefore, performed BBAL, which is simple, suitable for bacterial culture and does not require bronchoscopy [9] . Multiplex syndromic panels for the detection of bacterial pathogens responsible for pneumonia have recently been developed and shown to yield more sensitive results more rapidly than conventional culture, particularly in cases in which antibiotics were administered before sampling [6] [7] [8] . However, there are currently no recommendations for routine molecular testing and multiplex PCR is rarely used for detection of the bacteria typically responsible for pneumonia. Questions about the clinical usefulness of this approach remain, particularly in the context of critically ill patients with COVID-19. This is, to our knowledge, the first study to evaluate, in real-time, FA-PP relative to culture, using exclusively distal respiratory samples for the diagnosis of bacterial pneumonia in critically ill patients. It Bacterial cultures of BBAL grew with significant amount of bacteria (ie, ≥10 4 CFU/mL) in 37% (n =16) of patients. Among the 16 bacterial pneumonia, 4 (25%) were classified as community-acquired pneumonia, 1 (6%) as HAP, and 11 (69%) as VAP. In our study, 6% (6/96) of the samples were found to contain a bacterium not present in the FA-PP panel, and this bacterium was present at a high abundance (i.e. ≥ 10 4 CFU/mL) in four of these samples. These bacteria were involved in 1 HAP and 3 VAP. [7, 8] . In addition, resistance genes detected by FA-PP were not confirmed by AST results in 2 samples suggesting limitations to predict phenotypic susceptibility from molecular tests. These results raise important point that PCR can detect both dead and viable bacteria [7, 8, 12] . It remains unclear for how long bacterial loads remain detectable after the initiation of appropriate antibiotic treatment in critically ill patients with COVID-19 and whether the monitoring of bacterial load by FA-PP would be useful in these patients and, more broadly, in all patients with suspected VAP. Further studies are required to investigate this issue. Additionally, FA-PP has a cost per test much greater than the costs of routine culture; future studies should focus on how best to use this test in a cost-effective manner. Finally, the strengths of this study are the well-characterized population of patients (COVID-19 in ICU), the use of a single type of specimen (BBAL) and prospective testing by FA-PP and culture in parallel. Its J o u r n a l P r e -p r o o f limitations are that it was a single-center study and that the COVID-19 population may not be representative of the ventilated patients generally treated in the ICU In conclusion, in this prospective study of critically ill patient with COVID-19, FA-PP results were in agreement with standard culture for identifying bacterial pathogens in BBAL specimens, with a significant decrease of TAT. The use of FA-PP may enable a more complete and faster approach for the diagnosis of bacterial pneumonia in patient hospitalized in ICU. Further studies are required to address the clinical impact of FA-PP on the management of VAP in critically ill patients. Clinical and virological data of the first cases of COVID-19 in Europe: a case series Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Ventilator-associated pneumonia: present understanding and ongoing debates Ventilator-associated pneumonia in adults: a narrative review Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units Evaluation of the BioFire® FilmArray® Pneumonia Panel for rapid detection of respiratory bacterial pathogens and antibiotic J o u r n a l P r e -p r o o f Journal Pre-proof resistance genes in sputum and endotracheal aspirate specimens Blind and bronchoscopic sampling methods in suspected ventilator-associated pneumonia. A multicentre prospective study European Manual of Clinical Microbiology Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumonia The authors thank the intensive care teams and the clinical microbiology staff of Saint-Louis Hospital for their contributions. They also thank Samuel Amar for his help with the collection of microbiological data.